A citation-based method for searching scientific literature

Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John P H Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence A Leiter. Diabetes Obes Metab 2018
Times Cited: 35







List of co-cited articles
451 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
248
45

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
40

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
214
37

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain. Lancet Diabetes Endocrinol 2017
190
34

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
786
34

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
408
31

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted. Diabetes Obes Metab 2017
119
31

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
195
31

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
31


Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
390
28


Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood. J Clin Endocrinol Metab 2018
110
22


3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
278
20


A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Michael A Nauck, John R Petrie, Giorgio Sesti, Edoardo Mannucci, Jean-Pierre Courrèges, Marie L Lindegaard, Christine B Jensen, Stephen L Atkin. Diabetes Care 2016
110
17

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Caroline M Apovian, Louis Aronne, Domenica Rubino, Christopher Still, Holly Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich. Obesity (Silver Spring) 2013
271
17

Management of obesity.
George A Bray, Gema Frühbeck, Donna H Ryan, John P H Wilding. Lancet 2016
403
17

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
132
17

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
293
17

Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
Julie B Hjerpsted, Anne Flint, Ashley Brooks, Mads B Axelsen, Trine Kvist, John Blundell. Diabetes Obes Metab 2018
58
17

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan. Diabetes Care 2014
217
17

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Vanita R Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M Lalic, Enrique C Morales Villegas, Ole K Jeppesen, Erik Christiansen, Christin L Hertz, Martin Haluzík. Diabetes Care 2019
115
17

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
293
17

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
169
17


Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Thomas C Marbury, Anne Flint, Jacob B Jacobsen, Julie Derving Karsbøl, Kenneth Lasseter. Clin Pharmacokinet 2017
52
14

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
347
14

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
460
14

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
M E J Lean, R Carraro, N Finer, H Hartvig, M L Lindegaard, S Rössner, L Van Gaal, A Astrup. Int J Obes (Lond) 2014
107
14


Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden. Am J Clin Nutr 2012
349
14

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
532
14

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Thomas A Wadden, John P Foreyt, Gary D Foster, James O Hill, Samuel Klein, Patrick M O'Neil, Michael G Perri, F Xavier Pi-Sunyer, Cheryl L Rock, Janelle S Erickson,[...]. Obesity (Silver Spring) 2011
273
14



Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
908
14

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
14

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Yutaka Seino, Yasuo Terauchi, Takeshi Osonoi, Daisuke Yabe, Nobuyuki Abe, Tomoyuki Nishida, Jeppe Zacho, Shizuka Kaneko. Diabetes Obes Metab 2018
48
14

Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
92
14

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
148
14

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Thomas R Pieber, Bruce Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Signe O R Wallenstein, John B Buse. Lancet Diabetes Endocrinol 2019
94
14

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
307
14

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T Hietpas, Fady T Botros. Diabetes Metab Res Rev 2016
67
14

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
W Timothy Garvey, Jeffrey I Mechanick, Elise M Brett, Alan J Garber, Daniel L Hurley, Ania M Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack, Raymond Plodkowski. Endocr Pract 2016
451
14

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya. Diabetes Care 2019
112
14

Semaglutide lowers body weight in rodents via distributed neural pathways.
Sanaz Gabery, Casper G Salinas, Sarah J Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F Baquero, Stephen T Buckley, Erzsébet Farkas, Csaba Fekete, Klaus S Frederiksen,[...]. JCI Insight 2020
84
14

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Thomas A Wadden, Timothy S Bailey, Liana K Billings, Melanie Davies, Juan P Frias, Anna Koroleva, Ildiko Lingvay, Patrick M O'Neil, Domenica M Rubino, Dorthe Skovgaard,[...]. JAMA 2021
83
14

GLP-1 receptor agonists: a review of head-to-head clinical studies.
Jennifer M Trujillo, Wesley Nuffer, Samuel L Ellis. Ther Adv Endocrinol Metab 2015
183
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.